HOTH Hoth Therapeutics, Inc.

Hoth Therapeutics is a development stage biopharmaceutical company focused on proprietary therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. To treat indications impacting more than 32 million Americans, Hoth is working to develop and commercialize the BioLexa Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform has achieved positive results at preclinical studies conducted at the University of Miami.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/15/2019
Outstanding shares:  23,974,178
Average volume:  310,516
Market cap:   $19,318,393
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    44148G105
ISIN:        US44148G1058
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.34
PS ratio:   0.00
Return on equity:   -86.85%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy